Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes.
about
The role of circadian clocks in metabolic diseaseStandards of medical care in diabetes--2012Diabetes and Hypertension: A Comparative Review of Current GuidelinesAmbulatory blood pressure monitoring in the diagnosis and management of hypertensionAnalysis of recent papers in hypertension: nighttime administration of at least one antihypertensive medication is associated with better blood pressure control and cardiovascular outcomes in patients with type 2 diabetes or chronic kidney diseaseStandards of medical care in diabetes--2013Therapeutic Differences in 24-h Ambulatory Blood Pressures in Patients Switched Between Bioequivalent Nifedipine Osmotic Systems With Differing Delivery Technologies.Current issues in the management and monitoring of hypertension in chronic kidney disease.Efficacy and safety of nighttime dosing of antihypertensives: review of the literature and design of a pragmatic clinical trial.Nocturnal antihypertensive treatment in patients with type 1 diabetes with autonomic neuropathy and non-dipping of blood pressure during night time: protocol for a randomised, placebo-controlled, double-blind, two-way crossover study.Optimising the accuracy of blood pressure monitoring in chronic kidney disease: the utility of BpTRUManagement of hypertension in CKD: beyond the guidelines.PURLs: BP meds: this simple change improves outcomesEndothelial function in postmenopausal women with nighttime systolic hypertension.Taking blood pressure-lowering medications at night.Ethical complexities in standard of care randomized trials: A case study of morning versus nighttime dosing of blood pressure drugsMethods of a large prospective, randomised, open-label, blinded end-point study comparing morning versus evening dosing in hypertensive patients: the Treatment In Morning versus Evening (TIME) studyThe angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney diseaseDifferences in night-time and daytime ambulatory blood pressure when diurnal periods are defined by self-report, fixed-times, and actigraphy: Improving the Detection of Hypertension study.Circadian rhythm connections to oxidative stress: implications for human health.Ambulatory Blood Pressure in Chronic Kidney Disease: Ready for Prime Time?Hypertension and chronic kidney disease progression: why the suboptimal outcomes?Resistant hypertension: concepts and approach to management.'Time and time again': oscillatory and longitudinal time patterns in dialysis patients.Administration-time differences in effects of hypertension medications on ambulatory blood pressure regulation.Ambulatory blood pressure monitoring: recent evidence and clinical pharmacy applications.Timing is important in medication administration: a timely review of chronotherapy research.Chronotherapy improves blood pressure control and reduces vascular risk in CKD.Epidemiology, prognosis, and treatment of resistant hypertension.Trialogue Plus: Management of cardiovascular risk in hyperglycaemic/diabetic patients at hospital discharge.Chronotherapeutics of conventional blood pressure-lowering medications: simple, low-cost means of improving management and treatment outcomes of hypertensive-related disorders.Sleep-time ambulatory blood pressure as a novel therapeutic target for cardiovascular risk reduction.Around-the-clock ambulatory blood pressure monitoring is required to properly diagnose resistant hypertension and assess associated vascular risk.Current therapeutic approaches to cardio-protection in hypertension.Treatment of hypertension with chronotherapy: is it time of drug administration?Managing hypertension with ambulatory blood pressure monitoring.Controversies Among the Hypertension Guidelines.Cardiovascular risk reduction in hypertension: angiotensin-converting enzyme inhibitors, angiotensin receptor blockers. Where are we up to?Secondary Stroke Prevention: Improving Diagnosis and Management with Newer Technologies.Nocturnal antihypertensive treatment in patients with type 1 diabetes with autonomic neuropathy and non-dipping: a randomised, placebo-controlled, double-blind cross-over trial.
P2860
Q24597882-DB45584D-50B9-412D-9F37-706C10A0E140Q24632533-D541EE5B-98F4-4282-AEF1-2536E72101E1Q26800179-6C8FB8EE-5140-4E28-936D-9D287F8FB982Q26999957-7B35E57C-5605-4549-AD16-0D80C7210960Q27008919-85237F7B-B7AF-4D0B-9397-EECCEB8702CBQ29620309-87060FEB-4DD2-4B31-9E29-16C19BA3FA7EQ33648055-8084EFFB-D00D-4C5B-8DA7-F422A0E17CA0Q33858915-831DDCC8-4649-4DD9-9A6F-20AC72BBB454Q33881994-75BA0109-455F-41FA-811E-912670888D09Q34299198-B0D6533E-707A-430D-A668-0EC7DB3F9A0BQ35013404-82DFACA6-CBDF-485F-9226-F73EB8CA8775Q35651663-5AECFA42-D02A-408C-98BF-C87E393289E4Q35814432-236B12C6-CFA9-4871-9113-C8F1AD70947EQ35822959-3299F93D-E6C4-4A20-B1D1-CF52CF0CF783Q36229558-01363319-C5A8-4370-A9F6-FAE17FB7DB09Q36275898-2557F5A7-9F5A-47A8-A921-34145448FACCQ36602978-4B45477D-3E4E-43B6-88F7-65BC6A50ABDBQ36675029-E89BF2B5-9FC5-4434-AB54-92C456764D2FQ36676254-FC8E1E90-47A1-43FE-B1FE-4287DE7FB866Q36945752-E52ECC6D-2BAB-4129-9ED1-80C59353A3F5Q37616714-04A94191-E501-4F0B-B20C-92EBE60CBBC2Q37618602-68F7EF0A-5C21-4A4F-976C-1BBA8F4828DCQ37933093-631DF5D1-5D67-42B5-9390-D470BAFFFE06Q38034378-7449E898-AA7B-4340-BE5D-E75244BFCA87Q38053166-D103E9F1-FBDC-46E1-8A20-C9ACB006D778Q38073206-FF5F42AF-366B-4979-B41C-7A01A00D8F48Q38074873-236DE408-F14C-4CD6-AA84-ED6E50E4CC6AQ38100986-7AAED926-1028-48B6-9E4C-C5402C262B2DQ38110711-96CA4D1D-8866-4F92-9DF7-BA1A9E4E705EQ38152246-1430B4E0-9B4C-4247-A7A9-1940F360348FQ38177166-D2091557-5083-4596-A382-3425AFCC5B32Q38185598-13C4A242-3FD1-4F6C-85C6-0C591FF8A894Q38208966-4E3927F6-713E-482C-BEE7-68755C04BA70Q38223595-F88D59F7-C8A0-4A62-85B7-1206D0CB1FB7Q38291112-AF2A7E78-6F89-4784-B16C-26F4E0F1BE7EQ38331093-316888E2-F46F-4905-84B6-560DF4980F11Q38669552-8821D705-D2B9-468C-85D2-B55691B497CCQ38770466-BB651137-B07E-492D-B0C5-354B5DCF96A6Q38944341-189395CB-937A-4C43-8F27-2A32F4738D31Q39388581-B0F6A0B4-25B8-41AE-A151-804764D1CB57
P2860
Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Influence of time of day of bl ...... patients with type 2 diabetes.
@en
type
label
Influence of time of day of bl ...... patients with type 2 diabetes.
@en
prefLabel
Influence of time of day of bl ...... patients with type 2 diabetes.
@en
P2093
P2860
P356
P1433
P1476
Influence of time of day of bl ...... patients with type 2 diabetes
@en
P2093
Artemio Mojón
Diana E Ayala
Ramón C Hermida
P2860
P304
P356
10.2337/DC11-0297
P407
P577
2011-06-01T00:00:00Z